Marrow cell dose is a significant predictor of outcome in patients undergoing allogeneic hematopoietic stem cell tranplantation

Andrea Bacigalupo, Alida Dominietto, Teresa Lamparelli, Anna Maria Raiola, Maria Teresa Van Lint, Francesca Gualandi, Giovanni Berisso, Stefania Bregante, Carmen Di Grazia, Francesco Frassoni

Research output: Contribution to journalArticlepeer-review

Abstract

The influence of marrow cell dose on the outcome of allogeneic bone marrow transplantation (BMT) has been debated. The aim of this study was to evaluate the impact of grafted cell dose on graft function, graft-versus-host disease (GvHD) and transplant-related mortality (TRM). We report 851 consecutive patients grafted between 1976 and 1999 who received unmanipulated marrow, Median follow up for was 120 days (range 1 -6533) for deceased patients and 2412 days (range 180-8842) for surviving patients. The donor type was an HLA identical sibling (n=701), a mismatched related donor (n=33) or a matched unrelated donor (n=117). Median recipient age at transplant was 29 years (range 1-66). The disease was in early phase in 61% (n=518) of the patients. The conditioning regimen was cyclophosphamide (CY) alone (n=92), CY-total body irradiation (n=6i2), CY- thiotepa (n=93), or other combinations (n=54). Acute GvHD prophylaxis consisted of cyclosporin A with or without methotrexate. Median number of nucleated cells infused was 3.3 x 108/Kg (25 percentile 2.3xl08/Kg , 75 percentile 4.8xl08/Kg). Patients were stratified in three groups according to low, intermediate or high cell dose:

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART I
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Marrow cell dose is a significant predictor of outcome in patients undergoing allogeneic hematopoietic stem cell tranplantation'. Together they form a unique fingerprint.

Cite this